论文部分内容阅读
目的分析研究尤瑞克林联合依达拉奉治疗急性脑梗死临床疗效。方法 86例急性脑梗死患者,按照用药方法随机划分为对照组(46例)和研究组(40例),均先给予患者采用基础性治疗,对照组采用银杏达莫及胞二磷胆碱治疗,研究组在对照组治疗基础上结合采用尤瑞克林联合依达拉奉治疗,并根据卒中量表(NIHSS)评分、日常生活量表(ADL)评分评价用药治疗效果以及不良反应情况。结果对照组患者治疗有效率为80.4%,研究组患者的治疗有效率为97.5%,研究组治疗有效率明显优于对照组,差异有统计学意义(P<0.05)。用药治疗后两组患者的NIHSS评分明显下降,且研究组患者的下降明显优于对照组(P<0.05)。结论急性脑梗死患者临床用药治疗时采用尤瑞克林联合依达拉奉治疗,预后效果显著,应用安全可靠,值得应用推广。
Objective To analyze the clinical efficacy of uracil combined with edaravone in the treatment of acute cerebral infarction. Methods Eighty-six patients with acute cerebral infarction were randomly divided into control group (n = 46) and study group (n = 40). All patients were given basic treatment, while those in control group were treated with ginkgodam and citicoline . The study group was treated with uracil combined with edaravone. The NIHSS score and ADL score were used to evaluate the therapeutic effect and adverse reactions. Results The effective rate of treatment was 80.4% in control group and 97.5% in study group. The treatment efficiency in study group was significantly better than that in control group (P <0.05). NIHSS scores decreased significantly in both groups after treatment, and the decline in study group was significantly better than that in control group (P <0.05). Conclusion The clinical treatment of patients with acute cerebral infarction with uracil combined edaravone treatment, the prognosis is significant, the application of safe and reliable, it is worth to promote the application.